TD Cowen Reiterates Hold Rating for Fusion Pharmaceuticals (NASDAQ:FUSN)

Fusion Pharmaceuticals (NASDAQ:FUSN)‘s stock had its “hold” rating reissued by research analysts at TD Cowen in a research note issued on Tuesday, Benzinga reports.

A number of other equities analysts also recently commented on FUSN. Brookline Capital Management downgraded shares of Fusion Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, March 19th. Leerink Partnrs downgraded shares of Fusion Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Tuesday, March 19th. Oppenheimer upped their price objective on shares of Fusion Pharmaceuticals from $13.00 to $15.00 and gave the company an “outperform” rating in a research note on Friday, January 5th. Royal Bank of Canada restated a “sector perform” rating and issued a $21.00 price objective (up previously from $16.00) on shares of Fusion Pharmaceuticals in a research note on Wednesday, March 20th. Finally, Jefferies Financial Group restated a “hold” rating and issued a $21.00 price objective (up previously from $10.00) on shares of Fusion Pharmaceuticals in a research note on Tuesday, March 19th. Thirteen investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $20.25.

Fusion Pharmaceuticals Stock Down 0.1 %

Fusion Pharmaceuticals stock opened at $21.28 on Tuesday. Fusion Pharmaceuticals has a twelve month low of $2.31 and a twelve month high of $21.55. The stock’s fifty day simple moving average is $15.28 and its 200-day simple moving average is $9.41. The company has a current ratio of 15.01, a quick ratio of 15.01 and a debt-to-equity ratio of 0.16. The firm has a market capitalization of $1.80 billion, a P/E ratio of -14.48 and a beta of -0.73.

Fusion Pharmaceuticals (NASDAQ:FUSN) last posted its quarterly earnings data on Wednesday, March 20th. The company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.05). Fusion Pharmaceuticals had a negative return on equity of 46.59% and a negative net margin of 4,136.55%. As a group, equities analysts expect that Fusion Pharmaceuticals will post -1.46 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of FUSN. Federated Hermes Inc. lifted its holdings in shares of Fusion Pharmaceuticals by 1.9% during the 4th quarter. Federated Hermes Inc. now owns 10,886,153 shares of the company’s stock valued at $104,616,000 after acquiring an additional 202,364 shares in the last quarter. Avidity Partners Management LP lifted its holdings in Fusion Pharmaceuticals by 12.4% in the 4th quarter. Avidity Partners Management LP now owns 6,500,328 shares of the company’s stock worth $62,468,000 after buying an additional 718,478 shares in the last quarter. FMR LLC lifted its holdings in Fusion Pharmaceuticals by 73.9% in the 1st quarter. FMR LLC now owns 4,681,457 shares of the company’s stock worth $17,649,000 after buying an additional 1,989,403 shares in the last quarter. Perceptive Advisors LLC acquired a new position in Fusion Pharmaceuticals in the 1st quarter worth $10,405,000. Finally, Sphera Funds Management LTD. acquired a new position in Fusion Pharmaceuticals in the 1st quarter worth $4,839,000. 72.85% of the stock is currently owned by institutional investors and hedge funds.

Fusion Pharmaceuticals Company Profile

Fusion Pharmaceuticals Inc, a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. The company's lead product candidates include FPI-2265 that is in Phase 2 clinical trial to treat prostate-specific membrane antigens; and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing that target insulin-like growth factor 1 receptor.